G6PD and liver cancer: In order to further determine that the increased G6PD enzyme activity mediated by TSP50 is involved in metabolic reprogramming in liver cancer cells, RNA sequencing was performed and the results showed that the addition of the G6PD inhibitor RRx‐1 alters the expression levels of a large number of genes.